Pulmonx Corporation (LUNG)
| Market Cap | 53.64M -75.5% |
| Revenue (ttm) | 90.50M +8.0% |
| Net Income | -54.00M |
| EPS | -1.33 |
| Shares Out | 42.24M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 264,909 |
| Open | 1.270 |
| Previous Close | 1.280 |
| Day's Range | 1.230 - 1.280 |
| 52-Week Range | 1.130 - 5.459 |
| Beta | 0.19 |
| Analysts | Buy |
| Price Target | 5.38 (+323.62%) |
| Earnings Date | Apr 29, 2026 |
About LUNG
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with mult... [Read more]
Financial Performance
In 2025, Pulmonx's revenue was $90.50 million, an increase of 8.01% compared to the previous year's $83.79 million. Losses were -$54.00 million, -4.24% less than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for LUNG stock is "Buy." The 12-month stock price target is $5.38, which is an increase of 323.62% from the latest price.
News
Pulmonx to Report First Quarter 2026 Financial Results on April 29, 2026
REDWOOD CITY, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will...
Pulmonx Earnings Call Transcript: Q4 2025
Q4 2025 revenue declined year-over-year, but full-year revenue grew 8% with strong international performance. Cost restructuring and new financing improved financial flexibility, while U.S. sales force realignment and clinical trial progress set the stage for resumed growth in the second half of 2026.
Pulmonx Reports Fourth Quarter and Full Year 2025 Financial Results
REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today repor...
Pulmonx Announces Closing of up to $60 Million Credit Facility
Refinancing Strengthens Capital Structure by Extending Debt Maturity and Providing Access to Additional Undrawn Capital Refinancing Strengthens Capital Structure by Extending Debt Maturity and Providi...
Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
REDWOOD CITY, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will ...
Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announ...
Pulmonx Earnings Call Transcript: Q3 2025
Q3 2025 revenue grew 5% year-over-year to $21.5M, with international markets outpacing the U.S. Operating expenses and net loss remained high, but leadership is focused on realigning spending and improving profitability. Full-year revenue guidance is $89M-$90M.
Pulmonx Reports Third Quarter 2025 Financial Results
REDWOOD CITY, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today report...
Pulmonx Announces Management Transition and Preliminary Third Quarter 2025 Revenue; Reschedules Third Quarter 2025 Earnings Call to November 12, 2025
REDWOOD CITY, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announ...
Pulmonx to Report Third Quarter 2025 Financial Results on October 29, 2025
REDWOOD CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announ...
Pulmonx Transcript: Wells Fargo 20th Annual Healthcare Conference 2025
International growth is robust, with double-digit gains in Europe and strong prospects in Asia. U.S. growth is challenged by hospital capacity but supported by new tools, direct-to-patient outreach, and initiatives like LungTraX and AeriSeal. Financial discipline and margin improvement remain priorities.
Pulmonx to Participate in September Investor Conferences
REDWOOD CITY, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announ...
Pulmonx Transcript: Canaccord Genuity’s 45th Annual Growth Conference
A minimally invasive valve solution for severe emphysema is targeting a $12B global market, supported by strong clinical data and broad reimbursement. U.S. growth initiatives, including direct-to-patient outreach and AI-driven patient identification, are progressing but taking longer than expected, prompting revised revenue guidance and operational efficiencies.
Pulmonx Earnings Call Transcript: Q2 2025
Q2 2025 revenue grew 15% year-over-year to $23.9M, led by strong international performance, while U.S. growth lagged due to capacity constraints. Full-year revenue guidance was revised down to $90–$92M, but key commercial and clinical initiatives are gaining traction.
Pulmonx Reports Second Quarter 2025 Financial Results
REDWOOD CITY, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today report...
Pulmonx to Report Second Quarter 2025 Financial Results on July 30, 2025
REDWOOD CITY, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announ...
Pulmonx Transcript: Goldman Sachs 46th Annual Global Healthcare Conference
A large, underserved market for minimally invasive emphysema treatment is being addressed with strong clinical evidence, broad reimbursement, and innovative technology. Growth strategies include direct-to-patient outreach, AI-driven patient identification, and global expansion.
Pulmonx to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
REDWOOD CITY, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announc...
Pulmonx Transcript: Bank of America 2025 Healthcare Conference
A $12 billion global market exists for minimally invasive lung valve treatment, supported by strong clinical evidence and broad reimbursement. Patient acquisition is accelerating through direct advertising and AI-driven tools, with new products and geographic expansion set to drive further growth.
Pulmonx to Present at the Bank of America Securities 2025 Health Care Conference
REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the comp...
Pulmonx Earnings Call Transcript: Q1 2025
Q1 2025 revenue grew 20% year-over-year to $22.5M, led by strong international performance, especially in China. Full-year guidance of $96–$98M is reaffirmed, with US growth expected to accelerate in H2 as new commercial initiatives gain traction.
Pulmonx Reports First Quarter 2025 Financial Results
REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today repor...
EDAP Appoints Glen French to Board of Directors
PDF Version LYON, France, March 3, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, today announced the appointment of Glen French to ...
Pulmonx Transcript: Citi’s 2025 Medtech and Life Sciences Access Day
Strong year-over-year growth was achieved through strategic patient acquisition, workflow innovation, and international expansion. New software tools like LungTraX Connect and Detect are streamlining patient identification, while financial discipline supports confidence in reaching cash flow break even.
Top 3 Health Care Stocks You May Want To Dump In February
As of Feb. 20, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.